Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00529035 · ClinicalTrials.gov registry record · Phase 1
Ultra-Low Dose Interleukin-2 for Refractory Chronic Graft Versus Host Disease
A Phase 1 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
NCT00529035 is a Phase 1 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 29 participants.
The verdict
NCT00529035, a Phase 1 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
Study Summary
The purpose of this research study is to determine the safety of IL-2 and the highest dose of this drug that can be given safely to people with chronic graft versus host disease (GVHD). Chronic GVHD is a medical condition that may occur after patients receive a bone marrow, stem cell or cord blood transplant. The donor's immune system may recognize their body (the host) as foreign and attempt to "reject" it. Traditional standard therapy to treat chronic GVHD is prednisone (steroids). Treatment options are limited, and it is thought that IL-2 may help to control chronic GVHD.
Interventions
- DRUG Interleukin-2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2007-08 |
| Est. Completion | 2020-05-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00529035
The ClinicalTrials.gov registry entry for NCT00529035 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Interleukin-2 is the first listed.
NCT00529035 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00529035 about?
NCT00529035 is a clinical study titled "Ultra-Low Dose Interleukin-2 for Refractory Chronic Graft Versus Host Disease". The purpose of this research study is to determine the safety of IL-2 and the highest dose of this drug that can be given safely to people with chronic graft versus host disease (GVHD). Chronic GVHD is a medical condition that may occur after patients receive a bone marrow, stem cell or cord blood t...
What is the current status of trial NCT00529035?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2007-08. Estimated completion is 2020-05-27.
What interventions are being tested in trial NCT00529035?
The interventions under investigation include: Interleukin-2 (DRUG).
Who is sponsoring clinical trial NCT00529035?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.